FRα ADC新药Elahere：1st Q sales: 29.5M after launch
注射用，单价：6220；
FDA accelerated approval: Nov14, 2022 to treat adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
非一线用药